Form 4: Travere Therapeutics Executive Sells Shares
Insider Transaction (Form 4)
Elizabeth E Reed, Chief Legal Officer and GC of Travere Therapeutics, Inc., sold 37,500 shares of common stock on September 15, 2026.
Summary
- Option exercise/conversion: acquired 37,500 Common Stock at $15.46 ($579,750) on September 15, 2026; holds 142,889 after (Direct).
- Open-market sale: disposed of 21,926 Common Stock at $62.03 ($1,359,971) on September 15, 2026; holds 120,963 after (Direct).
- Open-market sale: disposed of 13,874 Common Stock at $62.63 ($868,965) on September 15, 2026; holds 107,089 after (Direct).
- Open-market sale: disposed of 1,400 Common Stock at $63.69 ($89,166) on September 15, 2026; holds 105,689 after (Direct).
- Open-market sale: disposed of 300 Common Stock at $65.31 ($19,593) on September 15, 2026; holds 105,389 after (Direct).
- Option exercise/conversion: disposed of 37,500 Employee stock option (right to buy) on September 15, 2026 (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $2,337,695 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Elizabeth E Reed — Officer (Chief Legal Officer and GC)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-15 | Option exercise/conversion | Common Stock | 37,500 | $15 | $579.8K | 142,889 |
| 2026-09-15 | Open-market sale | Common Stock | 21,926 | $62 | $1.4M | 120,963 |
| 2026-09-15 | Open-market sale | Common Stock | 13,874 | $63 | $869.0K | 107,089 |
| 2026-09-15 | Open-market sale | Common Stock | 1,400 | $64 | $89.2K | 105,689 |
| 2026-09-15 | Open-market sale | Common Stock | 300 | $65 | $19.6K | 105,389 |
| 2026-09-15 | Option exercise/conversion | Employee stock option (right to buy) | 37,500 | — | — | 0 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-15 | Option exercise/conversion (37,500 shares) |
| 2026-09-15 | Open-market sale (21,926 shares) |
| 2026-09-15 | Open-market sale (13,874 shares) |
| 2026-09-15 | Open-market sale (1,400 shares) |
| 2026-09-15 | Open-market sale (300 shares) |
| 2026-09-15 | Option exercise/conversion (37,500 shares) |
Keywords
insider transaction, Form 4, TVTX, Travere Therapeutics, Inc., bearish, Elizabeth E Reed
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.